On September 2, Twist Bioscience Corp rose 5.15% in regular trading, trading at 138.455 USD/share, with turnover of $21.8254 million. Notably, the stock initially dipped nearly 5% in early trading before staging a sharp reversal.

The rally is a continuation of momentum driven by Anthropic's earlier announcement of protein design breakthroughs using its Claude large language model. Anthropic's AI autonomously designed protein binders for 14 out of 15 clinical targets with virtually no human intervention, achieving an overall hit rate of 22.6% to 35.1% — roughly double the industry norm of 10% to 15%. Twist Bioscience served as one of two independent wet-lab validation platforms, responsible for large-scale rapid synthesis and binding-ability testing of the 1,320 AI-designed protein candidates. The partnership initially propelled the stock up over 17% in a single session in mid-August.

Separately, the company's fiscal Q3 results reported revenue of $118.376 million, beating estimates, while guiding Q4 revenue of $123 million to $124 million, also above the consensus estimate of $117.4 million, providing additional fundamental support.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)